NDA 213702 · Jazz
Zepzelca
Lurbinectedin · Intravenous · Alkylating Drug
NovelAccelerated approvalPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: Sep 30, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2020
Jun 15, 2020
Approved uses
2
Original approval plus efficacy supplements
Registered trials
65
12 Phase 3, 19 recruiting
FAERS reports
1,169
937 serious, 286 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Sep 30, 2026.
ZEPZELCA is an alkylating drug indicated: • in combination with atezolizumab or atezolizumab and hyaluronidase-tqjs, for the maintenance treatment of adult patients with extensive-stage small cell lung cancer whose disease has not progressed after first-line induction therapy with atezolizumab or atezolizumab and hyaluronidase-tqjs, carboplatin and etoposide. ( 1.1 ) 1.1 Extensive-Stage Small Cell Lung Cancer ZEPZELCA, in combination with atezolizumab or atezolizumab and hyaluronidase-tqjs, is indicated for the maintenance treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) whose disease has not progressed after first-line induction therapy with atezolizumab or atezolizumab and hyaluronidase-tqjs, carboplatin and etoposide.
Mechanism: Lurbinectedin is an alkylating drug that binds guanine residues in the minor groove of DNA, forming adducts and resulting in a bending of the DNA helix towards the major groove. Adduct formation triggers a cascade of events that can affect the subsequent activity of DNA binding proteins, including some transcription factors, and DNA repair pathways, resulting in perturbation of the cell cycle and eventual cell death. Lurbinectedin inhibited human monocyte activity in vitro and reduced macrophage infiltration in implanted tumors in mice.
Therapeutic areas: Oncology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Oct 2, 2025 Supplement 11 · Efficacy · priority review OrphanLabelLetter
- Jun 15, 2020 Original approval · Type 1 - New Molecular Entity · priority review NovelAccelerated approvalOrphanLabelLetterReview
1 products under this application
- ZEPZELCA · LURBINECTEDIN 4MG/VIAL · POWDER, INTRAVENOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Lurbinectedin" as an intervention, any sponsor and status, largest first.
- Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed Small-cell Lung Cancer (LAGOON)Pivotal-lookingCompleted
PharmaMarIndustry
NCT05153239 · 705 participants · Start Jul 22, 2022 · Primary completion Apr 10, 2026
Drug: Irinotecan; Lurbinectedin and 3 more · For: Relapsed Small Cell Lung Cancer
Sites: Chandler, Arizona; Hot Springs, Arkansas; Fort Myers, Florida · 210 sites in all
- A Study of Risvutatug Rezetecan in Combination With Atezolizumab in Participants With Extensive Stage Small Cell Lung Cancer (EMBOLD-SCLC-303)Pivotal-lookingNot yet recruiting
GlaxoSmithKlineGSK (GSK)
NCT07947121 · 700 participants (planned) · Start Dec 25, 2026 · Primary completion Feb 24, 2031
Drug: Ris-Rez; Atezolizumab and 3 more · For: Lung Neoplasm
- Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung CancerPivotal-lookingRecruiting
Gilead SciencesGilead Sciences (GILD)
NCT06801834 · 695 participants (planned) · Start Apr 4, 2025 · Primary completion Oct 2029
Drug: Sacituzumab Govitecan (SG); Topotecan and 2 more · For: Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Sites: Anchorage, Alaska; Hot Springs, Arkansas; Anaheim, California · 219 sites in all
- A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung CancerPivotal-lookingActive, not recruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT05091567 · 660 participants · Start Nov 18, 2021 · Primary completion Jul 29, 2024
Drug: Atezolizumab; Lurbinectedin and 2 more · For: Small-Cell Lung Cancer
Sites: Marietta, Georgia; Peoria, Illinois; Scarborough, Maine · 93 sites in all
- Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin Versus CAV or Topotecan as Treatment in Patients With Small-Cell Lung CancerPivotal-lookingCompleted
PharmaMarIndustry
NCT02566993 · 613 participants · Start Aug 30, 2016 · Primary completion Feb 24, 2020
Drug: Lurbinectedin (PM01183); Doxorubicin (DOX) and 3 more · For: Small-cell Lung Cancer
Sites: Birmingham, Alabama; Chandler, Arizona; Fullerton, California · 160 sites in all
- BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01)Pivotal-lookingRecruiting
SystImmune Inc.Industry
NCT07625644 · 550 participants (planned) · Start Aug 4, 2026 · Primary completion Jan 2030
Drug: BL-M14D1 and Atezolizumab; Carboplatin+ Etoposide + Atezolizumab followed by Atezolizumab and Lurbinectedin · For: Small Cell Lung Cancer Extensive Stage; Small-cell Lung Cancer; Small Cell Carcinoma and 5 more
Sites: Springdale, Arkansas; Glendale, California; Long Beach, California · 84 sites in all
- A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung CancerPivotal-lookingRecruiting
Daiichi SankyoDaiichi Sankyo (DSNKY)
NCT06203210 · 540 participants (planned) · Start May 21, 2024 · Primary completion Jan 30, 2028
Drug: Ifinatamab deruxtecan; Topotecan and 2 more · For: Small Cell Lung Cancer
Sites: Springdale, Arkansas; Fullerton, California; Los Angeles, California · 229 sites in all
- A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung CancerPivotal-lookingRecruiting
AbbVieAbbVie (ABBV)
NCT07365241 · 531 participants (planned) · Start Jul 2, 2026 · Primary completion Sep 2030
Drug: ABBV-706; Topotecan and 3 more · For: Small Cell Lung Cancer
Sites: Birmingham, Alabama; Mobile, Alabama; Goodyear, Arizona · 72 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- death150
- disease progression108
- neutropenia82
- off label use82
- nausea70
- thrombocytopenia60
- fatigue56
- febrile neutropenia47
- anaemia45
- asthenia45
- vomiting43
- injection site reaction36
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2013 | 1 |
| 2016 | 2 |
| 2017 | 1 |
| 2018 | 1 |
| 2020 | 54 |
| 2021 | 126 |
| 2022 | 244 |
| 2023 | 249 |
| 2024 | 180 |
| 2025 | 161 |
| 2026 | 150 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Zepzelca (Lurbinectedin)
2024 spending
$2.6M
Beneficiaries
43
169 claims
Per beneficiary
$59,767
$7,907.59 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $371,639 |
| 2021 | $1,211,475 |
| 2022 | $1,637,629 |
| 2023 | $2,435,684 |
| 2024 | $2,569,967 |
Part B: Zepzelca (Lurbinectedin) · HCPCS J9223
2024 spending
$115M
Beneficiaries
1,956
7,712 claims
Per beneficiary
$58,764
2024 ASP limit $201.47 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $88,260,768 |
| 2022 | $91,837,313 |
| 2023 | $105,340,083 |
| 2024 | $114,942,756 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy.
Mountzios G, Sun L, Cho BC, et al. · N Engl J Med 2025 · Randomized Controlled Trial, Multicenter Study
- Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trial.
Paz-Ares L, Borghaei H, Liu SV, et al. · Lancet 2025 · Randomized Controlled Trial, Clinical Trial, Phase III
- Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial.
Trigo J, Subbiah V, Besse B, et al. · Lancet Oncol 2020 · Clinical Trial, Phase II, Research Support, Non-U.S. Gov't
- Combination lurbinectedin and doxorubicin versus physician's choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial.
Aix SP, Ciuleanu TE, Navarro A, et al. · Lancet Respir Med 2023 · Randomized Controlled Trial, Multicenter Study
- Indirect treatment comparison of lurbinectedin versus other second-line treatments for small-cell lung cancer.
Hanvesakul R, Rengarajan B, Naveh N, et al. · J Comp Eff Res 2023 · Systematic Review, Research Support, Non-U.S. Gov't
- Lurbinectedin Plus Pembrolizumab in Relapsed SCLC: The Phase I/II LUPER Study.
Calles A, Navarro A, Doger de Speville Uribe BG, et al. · J Thorac Oncol 2025 · Clinical Trial, Phase I, Clinical Trial, Phase II
Sponsor: Jazz Pharmaceuticals
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.